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The mechanism of the antianginal actions of nilvadipine
was investigated in 11 patients with effort angina pec-
toris. Hemodynamic data were obtained by angina-lim-
ited supine multistage bicycle ergometer exercise testing
before and after a single 6 mg dose of nilvadipine.
Compared with chest pain during control exercise
testing, pain at peak exercise disappeared or abated and
the ST segment at peak exercise also showed less sig-
nificant depression after administration of nilvadipine.
At rest and at peak exercise, mean blood pressure, pul-
monary artery wedge pressure and systemic vascular
resistance decreased significantly, whereas heart rate and
cardiac index increased significantly after nilvadipine.
Rate-pressure product and stroke volume index did not
Nilvadipine (FR34235) is a new calcium channel blocking
agent that is chemically designated as 5-isopropyl 3-methyl
2-cyano-1 ,4-dihydro-6-methyl-4-(m-nitrophenyl)-3,5-pyri-
dinedicarboxylate. This drug has the same dihydropyridine
derivative as nifedipine (Fig. I) . Nilvadipine has been re-
ported (1,2) to act more selectively on the vascular smooth
muscle than on the cardiac muscle . Its calcium channel
blocking action was 5 to 16 times greater than that of ni-
fedipine (I) and the duration of this action was 2 to 3 times
longer than that of nifedipine (I) . Clinical studies (3) have
reported that nilvadipine decreases the frequency of anginal
attacks in patients with angina pectoris. However, the effects
of nilvadipine on hemodynamic changes in exercise-induced
angina pectoris and the mechanism of its antianginal action
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change significantly. Coronary sinus flow at peak ex-
ercise increased significantly and total coronary vascular
resistance at rest and at peak exercise decreased signif-
icantly after nilvadipine. The plasma concentrations of
nilvadipine 1.5 hours after administration ranged from
LIS to 8.23 ng/m!.
These data suggest that the principal factors in the
antianginal actions of nilvadipine are an increase in myo-
cardial oxygen supply due to increased coronary blood
flow and a reduction in myocardial oxygendemand mainly
by a decrease in afterload and additionally by a decrease
in preload.
(J Am Coil Cardiol 1987;10:830-6)
in patients with effort angina pectoris have not been elu -
cidated .
The present study evaluates the effect of nilvadipine on
hemodynamic changes in exercise-induced angina pectoris
and investigates its antianginal mechanism in patients with
stable effort angina pectoris subjected to dynamic leg ex-
ercise before and after oral administration of a single dose
of 6 mg of nilvadipine .
Methods
Study patients. The study group comprised II patients
with stable effort angina pectoris admitted to the Nagoya
University Hospital between August 1985 and July 1986.
The patients had had a transient attack of chest pain with
significant ischemic ST depression on angina-limited supine
multistage bicycle ergometer exercise . Their ages ranged
from 37 to 68 years (average 55 .7) . There were 10 men and
I woman and 5 of these II patients had a past history of
myocardial infarction (Table 1). Each subject was informed
in detail of the purpose and method of this study and gave
written informed consent.
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Hemodynamic studies. A triple lumen thermistor Swan-
Ganz catheter was positioned in the pulmonary artery per-
cutaneously through the brachial vein to measure cardiac
output and pulmonary artery wedge pressure. Thermodi-
lution technique was used to determine cardiac output. A
double thermistor catheter (CCSI7U-GOK. Wilton-Webster
Laboratories) was placed percutaneously in the coronary
sinus. The distal external thermistor was advanced to the
great cardiac vein, and the proximal external thermistor was
positioned in the coronary sinus between the ostium and the
termination of the middle cardiac vein under fluoroscopic
guidance to measure coronary sinus flow (4.5). A Teflon
catheter was also cannulated in the radial artery for direct
measurement of arterial pressure.
Bicycle ergometer exercise testing. Angina-limited bi-
cycle ergometer exercise testing was performed with pa-
tients in the supine position before administration of nil-
Nifed ipine
vadipine to obtain control values (6-8 ). The exercise end
point in the control study was moderate chest pain. The
work load was started at 25 Wand increased by 25 W at 3
minute intervals. A single oral dose of 6 mg of nilvadipine
was administered at the end of the control exercise test and
exercise testing using the same method, duration and work
load was performed [.5 hours after drug administration.
During exercise testing, an electrocardiogram (ECG) (CM~.
CC, . V.1 and Frank X. Y and Z leads) and systemic and
coronary hemodynamic variables were recorded.
Cardiac catheterization. All other drugs except sublin-
gual nitroglycerin for relief of chest pain were withdrawn
by 3 days before the study. Selective coronary arteriography
and left ventriculography were performed after the nilva-
dipine study. Left ventricular volume was calculated by the
use of biplane cineangiocardiography (9).
Measurement of plasma concentration of nilvadipine .
Blood sampling was done immediately before exercise test-
ing and 1.5 hours after administration of nilvadipine. The
plasma concentrations of nilvadipine were measured by cap-
illary column gas chromatography-negative ion chemical
ionization mass spectrometry (10).
Calculations. ST segment changes were expressed by
the maximal value (mean of three consecutive heartbeats)
of ischemic ST segment depression in any of the six leads
recorded and were measured with a magnifying glass 80 ms
from the J point. The level of two consecutive PR segments
was taken as the zero reference. Hemodynamic variables
were calculated as follows: rate-pressure product = systolic
blood pressure x heart rate; cardiac index (liters/min per
CH3
COOCH3
N0 2
Nilvad ipine
N0 2
CH3
I
H3COOC COOCH
I
CH3
N=C CH3 H3C
Table I. Sum mary of Pertinen t C lin ical and A ngiograph ic Findi ngs in II Pat ients
Coron ary Angiogra m
Age (yr) Exercise (% diameter reduction ) Left Ven tricular Angiogram
Case & Sex Time Is) LMT LAD LCx RCA Ef ( Cff) Wall Mot ion
A. Effort angina without old myocardi al infarction (n = 6)
I 68F 21X) 0 99 99 99 89 Lower posterior hypokinesia
2 57M 300 0 99 0 100 7 1 Anie roseptul hypok inesia
3 56M 480 0 75 75 0 85 Norm al
4 58M 540 75 90 75 90 63 Inferobasal seve re hypok inesia
and apica l hypokinesia
5 5l M 520 0 100 0 0 72 Anteroinferior hypokinesia
6 63M 540 0 0 90 75 82 Normal
B. Effort angina with old myocardial infarction (n = 5)
7 57M 540 0 100 90 90 66 Anterolateral and septal akinesia
8 5 1M 540 0 \00 0 95 80 Anterior hypokinesia*
9 53M 495 0 0 99 100 5 1 Inferoposterior akinesia
10 37M 540 0 0 100 I(X) 62 Inferobasal akinesia and high
posterior seve re hypokinesia
II 62M 210 0 90 100 90 39 Arnerosep tal severe hypokinesia
*In this case the left anterior descending artery was tilled by good collate ral circ ulation from the right coro nary artery and its first diagonal branch .
EF = ejection fraction; F = female; LAD = left anterior descending artery; LCx = left circumflex artery; LMT = left main trunk; M = male; RCA
= right coronary artery .
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Figure 2. Effectsof nilvadipine on exercise-induced maximal ST
depression. Ischemic ST depression induced by supine bicycle
ergometer exercise was improved by oral administration of nil-
vadipine in all of the II patients evaluated.
Results
Effects of nilvadipine on exercise-induced chest pain
and ischemic ST depression. The bicycle ergometer ex-
ercise time of the subjects studied ranged from 200 to 540
seconds (mean 446 ± 42). Moderate chest pain was induced
in all II patients studied during the control exercise test,
but after nilvadipine administration was not induced in 7
and was of lessened severity in 4. Comparative analysis of
exercise-induced ischemic ST depression before and after
nilvadipine administration was possible in all patients (Fig.
2). Exercise-induced ST depression was 0.22 ± 0.04 mV
in the control period, but was significantly reduced to 0.09
± 0.02 mV after administration of nilvadipine (p < 0.00 I).
Effects of nilvadipine on systemic hemodynamics (Ta-
ble 2). Heart rate increased significantly at rest and at peak
exercise after nilvadipine administration (p < 0.001 and p
< 0.05, respectively), whereas mean arterial pressure de-
creased significantly at rest and at peak exercise (both p <
0.00 I). Cardiac index (measured in 10 patients) increased
significantly at rest and at peak exercise after nilvadipine
(p < 0.001 and p < 0.05, respectively). After nilvadipine,
stroke work index decreased significantly at rest (p < 0.0 I),
but showed no significant changes at peak exercise. Stroke
volume index showed no significant changes at rest and at
peak exercise after nilvadipine.
In the control bicycle ergometer test, a marked elevation
of pulmonary artery wedge pressure with an increase in work
load was observed, but after nilvadipine administration, pul-
monary artery wedge pressure decreased significantly at rest
and during exercise (Fig. 3). After nilvadipine, systemic
vascular resistance decreased significantly at rest and during
exercise and recovery (Fig. 4). Changes in rate-pressure
product during exercise testing were not significantly mod-
ified by nilvadipine (Fig. 5).
Changes in cardiac function curves are shown by the
relation between pulmonary artery wedge pressure and stroke
work index in Figure 6. Cardiac function curves during the
control period were slightly deviated to the right and upward
at peak exercise in all patients studied. However, after nil-
vadipine administration, the increase in pulmonary artery
NilvadipineControl
-0.1
-0.3
-0.5
-0.4
rrr') = cardiac output/body surface area; stroke volume in-
dex (ml/rn") = cardiac index/heart rate; systemic vascular
resistance (dynes-s-cm -5) = mean arterial pressure/cardiac
output x 80; stroke work index (g-rn/beat per rn/) = stroke
volume index x (mean arterial pressure - mean pulmonary
artery wedge pressure) x 0.0136; and total coronary re-
sistance (mm Hg/ml per min) = mean arterial pres-
sure/coronary sinus flow.
Statistics. For statistical analysis, a paired t test was
performed; a probability (p) value <0.05 was considered
statistically significant. Data are expressed as mean ± SEM.
Table 2. Changes in Left Ventricular and Systemic Hemodynamic Responses to Supine Bicycle ErgometerExercise Before and After
Nilvadipine in II Patients With Stable Angina Pectoris
Control Period Nilvadipine Period
Baseline Peak Exercise Baseline Peak Exercise
Heart rate (beats/min)
Blood pressure (mm Hg)
Systolic
Diastolic
Mean
Rate-pressure product ( x 102)
Pulmonary artery wedge pressure (mm Hg)
Cardiac index (liters/min per rrr')
Stroke volume index (ml/m'')
Stroke work index (g-m/beat per m2)
Systemic vascular resistance (dynes-s-cm -5)
68 ± 4
167 ± 9
91 ± 5
117 ± 6
114 ± 9
7 ± 1
2.80 ± 0.12
44 ± 3
64 ± 5
2,056 ± 156
115 ± 6
204 ± 13
103 ± 6
137 ± 8
238 ± 25
22 ± 3
5.19 ± 0.33
47 ± 3
70 ± 6
1.316 ± 138
81 ± 4t
137 ± 7t
77 ± 4t
97 ± 5:1:
llO±1O
5 ± 1*
3.38 ± 0.19t
44 ± 3
53 ± 4t
1,415 ± 121t
125 ± 6*
188 ± 15t
92 ± 6t
124 ± 9t
241 ± 31
10 :t 3:}
5.99 :t 0.46*
50 ± 4
73 :t 7
1,025 ± 96t
*p < 0.05; tp < 0.01; tp < 0.001. Values are means ± SEM. Hemodynamic variables at rest and at peak exercise were compared between the
control and the nilvadipine period, respectively.
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Figure 3. Marked elevation of pulmonary artery wedge pressure
(PAWP) with increase in work load was observed in control supine
bicycle ergometer testing, but after administration of nilvadipine
a significant decrease in pulmonary artery wedge pressure was
noted throughout exercise.
10 ' 2X 10' 3X 10' 4X10' Sx 10'
RPP (Control)
Figure 5. The changes in rate-pressure product (RPP) during ex-
ercise testing were not significantly modified by nilvadipine.
wedge pressure was small, whereas the increase in stroke
work index was remarkable, shifting the cardiac function
curve sharply upward to the left.
Effects of nilvadipine on coronary hemodynamics
(Table 3). Comparative analysis of coronary blood flow
was possible in seven patients with stable effort angina
pectoris during bicycle ergometer exercise. In the control
period, exercise induced an increase in coronary sinus flow
and a decrease in total coronary resistance. After admin-
istration of nilvadipine, coronary sinus flow increased slightly
at rest (p < 0. 10)and increased significantly at peak exercise
(p < 0.05). Totalcoronary resistance decreased signifi cantly
at rest and at peak exercise (both p < 0.05). The ratio of
rate-pressureproduct to coronary sinus flow decreased slightly
at rest and at peak exercise (both p < 0.10).
Changes in plasma concentrations of nilvadipine.
Plasma concentrations of nilvadipine in seven patients whose
Figure 4. After administration of nilvadipine a significant de-
crease in systemic vascular resistance (SVR) was noted throughout
exercise testing.
blood sample could be collected 1.5 hours after adminis-
tration of the drug ranged from l.15 to 8.23 ng/ml (average
3.57 ± 0.89).
Discussion
Effects of nilvadipine. In this study using bicycle er-
gometer exercise testing, administration of a single oraldose
of nilvadipine resultedin disappearance or lesseningof chest
pain and significant alleviation of ischemic ST depression
and improvement in cardiac function curves depicted from
the relation between pulmonary artery wedge pressure and
left stroke work index compared with the control study.
These results suggest that nilvadipine has clear-cut effects
Figure 6. Effects of nilvadipine on the relation between pulmo-
nary artery wedge pressure (PAWP) and stroke work index (SWl).
Afteradministration of nilvadipine the increase in pulmonaryartery
wedge pressure was very small. whereas the increase in stroke
work index was remarkable, shifting the cardiac function curve
change sharply upward.
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Table 3. Changes in Coronary Hemodynamic Responses to Supine Bicycle Ergometer Exercise Before and After Nilvadipine in
Seven Patients With Stable Angina Pectoris
Control Period Nilvadipine Period
Coronary sinus flow (mllmin)
Total coronary resistance (mm Hg/rnl per min)
Rate-pressure product/coronary sinus flow- I02 (mm Hg-beat/rnl)
Baseline
138 ± 26
0.98 ± 0.16
1.14 ± 0.26
Peak Exercise
227 ± 29
0.65 ± 0.14
l.ll ± 0.25
Baseline
180 ± 19*
0.59 ± 0.08t
0.77 ± 0.13*
Peak Exercise
366 ± 52t
0.37 ± 0.07t
0.73 ± 0.16*
*p < 0.10; tp < 0.05. Values are means ± SEM. Coronary hemodynamic variables at rest and at peak exercise were compared between the control
and the nilvadipine period, respectively.
on both angina and objective indexes of coronary blood
flow.
Reproducibility of exercise test results. Exercise time,
heart rate and left ventricular end-diastolic pressure mea-
surements for evaluation of left ventricular function are gen-
erally said to be reproducible in patients with stable effort
angina pectoris subjected to symptom-limited bicycle er-
gometer exercise (11,12). We also demonstrated excellent
reproducibility in heart rate, rate-pressure product and car-
diac output at rest and during exercise in patients subjected
to two periods of bicycle ergometer exercise separated by
I hour (Yokota M. et aI, unpublished data). Accordingly,
the hemodynamic effects of nilvadipine observed in this
study should be reliable.
A single dose effect of nilvadipine. The routine daily
dose of nilvadipine for patients with effort angina pectoris
was 12mg in the clinical studies reported (3). We previously
examined the exercise tolerance of 15 patients with effort
angina pectoris using treadmill exercise at 2, 4 and 7 hours
after a single dose of 6 mg of nilvadipine in a double-blind
placebo control study (Noda S. et ai, unpublished data).
Significant prolongation of treadmill exercise time was ob-
served in this group even after 7 hours. Accordingly, 6 mg
of nilvadipine used in the present study seems to be appro-
priate for a single dose study.
Hemodynamic effects of nilvadipine and its antian-
gmal mechanism. Major changes in the hemodynamic re-
sponse after a single oral dose of nilvadipine were observed
at rest and during exercise in this study. These were a
decrease in systemic vascular resistance associated with a
marked depression of mean blood pressure and an increase
in cardiac output, a marked decrease in pulmonary artery
wedge pressure and an increase in coronary blood flow.
Heart rate increased at rest and at peak exercise after admin-
istration of nilvadipine, but the rate-pressure product, which
is believed to reflect myocardial oxygen consumption (13),
did not change at rest or during exercise. An increase in
heart rate may be caused by a reflex sympathetic stimulating
action originating from marked dilation of systemic vascular
vessels as in the case of other calcium channel blockers
based on dihydropyridine derivatives (14).
Myocardial oxygen consumption is regulated by the three
principal factors of myocardial contractility, heart rate and
cardiac wall tension (15). It is reported (7, 16-1S) that left
ventricular end-diastolic pressure and pulmonary artery wedge
pressure increase remarkably in patients with effort angina
pectoris subjected to exercise-induced anginal attacks. This
excessive elevation of left ventricular end-diastolic pressure
and pulmonary artery wedge pressure during ischemia is
considered to be due to abnormal ventricular compliance
(19-21) or to a lesser impairment of contractility (22-24).
The marked decrease in pulmonary artery wedge pressure
after administration of nilvadipine was probably caused by
an alleviation of myocardial ischemia or a decrease in its
severity. Pulmonary artery wedge pressure reflects the left
ventricular end-diastolic pressure (25), and an increase in
the latter correlates with an increase in left ventricular end-
diastolic volume (26). Accordingly, it is believed that nil-
vadipine decreases left ventricular wall tension and conse-
quently decreases myocardial oxygen consumption.
Myocardial contractility is a principal factor regulating
myocardial oxygen consumption. However, nilvadipine is
considered not to affect myocardial contractility or rate of
rise in left ventricular pressure (dP/dt) at a dose leading to
dilation of systemic vascular vessels (27). Therefore, the
decrease in oxygen demand is not caused by a decrease in
myocardial contractility. This drug did not affect the rate-
pressure product (13), which presumably reflects myocardial
oxygen consumption. Therefore, decreased myocardial wall
tension after administration of nilvadipine would be the main
factor causing decreased myocardial oxygen consumption.
On the other hand, the principal factors regulating myo-
cardial oxygen supply are coronary blood flow and oxygen-
carrying capacity. Nilvadipine increased coronary sinus flow
at peak exercise and decreased coronary resistance both at
rest and during exercise. This suggests increased myocardial
oxygen supply due to an increase in coronary blood flow.
In fact, the ratio of rate-pressure product to coronary sinus
flow, which is an index of the ratio of myocardial oxygen
consumption to myocardial oxygen supply, decreased mark-
edly after administration of nilvadipine. This finding sub-
stantiates the view that nilvadipine is expected to enhance
myocardial oxygen supply accompanying increased coro-
nary blood flow.
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Comparison of calcium channel blockers. Nifedipine,
diltiazem and verapamil have been commercially available
for treatment of effort angina pectoris. Previous reports
(28-30) suggest that the main mechanism of the antianginal
action of nifedipine is a decrease in afterload and a lessening
of myocardial ischemia. There is no consensus on the effect
of nifedipine on preload because it has been reported to have
variable effects on ventricular preload (28, 31-34) . Jim and
Matthews (35) observed that both nilvadipine and nifedipine
are potent antagonists of the voltage-dependent Ca2 ' chan-
nels, and that nilvadipine is a more effective antagonist of
receptor-operated Ca2+ entry in the Canine saphenous vein
than is nifedipine. As a result, nilvadipine is considered to
have a more potent calcium antagonist action in the vein
than that of nifedipine. A reduction in pulmonary artery
wedge pressure at rest and during exercise after adminis-
tration of nilvadipine is probably partly related to direct
action of nilvadipine on capacitance vessels.
Pharmacokinetics of nilvadipine. The pharmacokinet-
ics of nilvadipine were examined in healthy volunteers (Ter-
akawa M. et al., unpublished data). The plasma concentra-
tions of nilvadipine after oral administration of a single 6
mg dose peaked at 6.69 ± 1.54 ng/rnl (mean ± SD) 0.5
to 3 hours after dosing. The half-life of the elimination phase
is reported to be 11.0 ± 2.3 hours. In our study. bicycle
ergometer exercise testing was performed 1.5 hours after
administration of nilvadipine at the plasma concentrations
of 1.15 to 8.23 ng/ml. We considered that these plasma
concentrations of nilvadipine would be sufficient for its an-
tianginal action.
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